Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
EWTX
EWTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
EWTX News
Analyst Reiterates Bullish Stance on Edgewise Stock
5d ago
Fool
Analyst Reiterates Bullish Stance on Edgewise
5d ago
NASDAQ.COM
iShares U.S. Pharmaceuticals ETF Declines 1.8% on Thursday
Jan 15 2026
NASDAQ.COM
Edgewise Therapeutics CEO to Present at 44th J.P. Morgan Healthcare Conference
Jan 06 2026
Newsfilter
Edgewise Grants 119,250 Stock Options to New Employees Under Inducement Plan
Jan 05 2026
Newsfilter
Foresite Capital Fully Exits Edgewise Therapeutics, Incurring $7.67 Million Loss
Dec 30 2025
NASDAQ.COM
Foresite Capital Exits Edgewise Therapeutics, Reduces Stake by $7.67 Million
Dec 29 2025
Fool
Foresite Capital Fully Exits Edgewise Therapeutics, Incurring $7.67 Million Loss
Dec 29 2025
Yahoo Finance
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
Dec 26 2025
NASDAQ.COM
Edgewise Therapeutics Reports Positive Phase 2 Data, Shares Surge 26%
Dec 25 2025
Fool
Edgewise Therapeutics Reports Promising Phase 2 Data, Stock Surges 26%
Dec 25 2025
NASDAQ.COM
U.S. Stocks Rise with Dow Jones Surging Over 200 Points
Dec 24 2025
Benzinga
Sanofi Acquires Dynavax for $15.50 per Share, Totaling $2.2 Billion
Dec 24 2025
Benzinga
Edgewise Therapeutics Updates EDG-7500 Phase 2 Trial Progress, Shares Rise 17.96%
Dec 24 2025
Benzinga
Edgewise Completes Phase 2 CIRRUS-HCM Trial for EDG-7500 with Favorable Safety Results
Dec 24 2025
NASDAQ.COM
Edgewise Therapeutics Reports Positive Updates on EDG-7500 in CIRRUS-HCM Trial
Dec 24 2025
PRnewswire
Show More News
